
SUNLENCA (LENACAPAVIR INJ.)
Price
FAQ's
Details
Patients Stories
Important Guide
Lenacapavir is a first-in-class HIV-1 capsid inhibitor indicated for the treatment of multidrug-resistant HIV-1 infection. It works by targeting the viral capsid protein and disrupting multiple stages of the HIV life cycle. Its long-acting formulation allows administration as a subcutaneous injection every six months, offering a novel treatment option for patients with limited therapeutic choices.
